

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
15 September 2022 (15.09.2022)



(10) International Publication Number  
**WO 2022/189942 A1**

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)  
A61P 35/00 (2006.01) C12Q 1/6886 (2018.01)

(21) International Application Number:

PCT/IB2022/052009

(22) International Filing Date:

07 March 2022 (07.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/158,552 09 March 2021 (09.03.2021) US

(71) Applicant: JANSSEN BIOTECH, INC. [US/US];  
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044  
(US).

(72) Inventors: HENLEY, Benjamin J.; 1400 McKean Road,  
Spring House, Pennsylvania 19477 (US). MOORES, Sheri  
L.; 1400 McKean Road, Spring House, Pennsylvania 19477  
(US).

(74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson,  
One Johnson & Johnson Plaza, New Brunswick, New Jer-  
sey 08933 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii))


Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed  
contained color or greyscale and is available for download  
from PATENTSCOPE

(54) Title: TREATMENT OF CANCERS LACKING EGFR-ACTIVATING MUTATIONS

FIG. 1A

EGFR IHC vs. PLA in 39 Lung PDX Samples



(57) Abstract: The present invention relates to treatment of subjects having cancers with tumors lacking an at least one EGFR-activating mutation.